NervGen Pharma Valuation

Is NGEN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NGEN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NGEN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NGEN's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NGEN?

Key metric: As NGEN is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for NGEN. This is calculated by dividing NGEN's market cap by their current book value.
What is NGEN's PB Ratio?
PB Ratio	17.1x
Book	CA$9.18m
Market Cap	CA$160.19m

NGEN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-6.1x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does NGEN's PB Ratio compare to its peers?

The above table shows the PB ratio for NGEN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	5.4x
RX BioSyent	3.7x	n/a	CA$126.5m
AYR.A Ayr Wellness	0.2x	42.4%	CA$115.0m
CRDL Cardiol Therapeutics	16.7x	22.9%	CA$183.0m
PLTH Planet 13 Holdings	0.9x	n/a	CA$195.1m
NGEN NervGen Pharma	17.1x	n/a	CA$160.2m

Price-To-Book vs Peers: NGEN is expensive based on its Price-To-Book Ratio (17.1x) compared to the peer average (5.4x).

Price to Book Ratio vs Industry

How does NGEN's PB Ratio compare vs other companies in the CA Pharmaceuticals Industry?

9 Companies	Price / Book	Estimated Growth	Market Cap
AVNT Avant Brands	0.1x	n/a	US$4.93m
BZAM BZAM	0.08x	n/a	US$4.88m
CPTR Captor Capital	0.07x	n/a	US$1.99m
IDVR INDVR Brands	0.1x	n/a	US$1.17m

9 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: NGEN is expensive based on its Price-To-Book Ratio (17.1x) compared to the Canadian Pharmaceuticals industry average (1x).

Price to Book Ratio vs Fair Ratio

What is NGEN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NGEN PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	17.1x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate NGEN's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NGEN forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	CA$2.24	CA$4.50 +100.9%	11.1%	CA$5.00	CA$4.00	n/a	2
Nov ’25	CA$2.59	CA$4.50 +73.7%	11.1%	CA$5.00	CA$4.00	n/a	2
Oct ’25	CA$2.42	CA$4.50 +86.0%	11.1%	CA$5.00	CA$4.00	n/a	2
Sep ’25	CA$2.78	CA$4.50 +61.9%	11.1%	CA$5.00	CA$4.00	n/a	2
Aug ’25	CA$2.98	CA$4.50 +51.0%	11.1%	CA$5.00	CA$4.00	n/a	2
Jul ’25	CA$2.69	CA$4.50 +67.3%	11.1%	CA$5.00	CA$4.00	n/a	2
Jun ’25	CA$1.95	CA$4.50 +130.8%	11.1%	CA$5.00	CA$4.00	n/a	2
May ’25	CA$2.05	CA$4.50 +119.5%	11.1%	CA$5.00	CA$4.00	n/a	2
May ’24	CA$1.56	CA$5.25 +236.5%	14.3%	CA$6.00	CA$4.50	CA$2.05	2
Apr ’24	CA$1.64	CA$5.25 +220.1%	14.3%	CA$6.00	CA$4.50	CA$2.18	2
Mar ’24	CA$1.89	CA$5.25 +177.8%	14.3%	CA$6.00	CA$4.50	CA$3.36	2
Feb ’24	CA$2.22	CA$5.25 +136.5%	14.3%	CA$6.00	CA$4.50	CA$2.93	2
Jan ’24	CA$1.60	CA$5.25 +228.1%	14.3%	CA$6.00	CA$4.50	CA$2.70	2
Dec ’23	CA$1.88	CA$5.25 +179.3%	14.3%	CA$6.00	CA$4.50	CA$1.75	2
Nov ’23	CA$1.88	CA$5.25 +179.3%	14.3%	CA$6.00	CA$4.50	CA$1.88	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Fennec Pharmaceuticals

US$117.3m

Operates as a biopharmaceutical company in the United States.

FRX

US$6.50

7.6%

-44.2%

Medexus Pharmaceuticals

CA$52.0m

Operates as a pharmaceutical company in Canada and the United States.

MDP

CA$2.15

5.4%

40.5%

Verano Holdings

CA$850.9m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$2.32

-12.8%

-60.6%